Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:APLS - US03753U1060 - Common Stock

23.79 USD
+0.16 (+0.68%)
Last: 12/8/2025, 8:00:00 PM
24 USD
+0.21 (+0.88%)
After Hours: 12/8/2025, 8:00:00 PM
Buy % Consensus

78

ChartMill assigns a Buy % Consensus number of 78% to APLS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 36.24. This target is 52.32% above the current price.
APLS was analyzed by 28 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about APLS.
In the previous month the buy percentage consensus was at a similar level.
APLS was analyzed by 28 analysts, which is quite many. So the average rating should be quite meaningful.
APLS Historical Analyst RatingsAPLS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -95 -86 -77 -68 -59 -50 -41 -32 -23 -14 -5 5 10 15 20 25

Price Target & Forecast

Price Low Median Mean High 23.7919.1936.7236.2457.75 - -19.34% 54.35% 52.32% 142.75%
APLS Current Analyst RatingAPLS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10
Up and Down Grades
Date Firm Action Rating
2025-11-06 Wolfe Research Initiate Peer Perform
2025-11-05 JP Morgan Maintains Overweight -> Overweight
2025-11-03 Mizuho Maintains Neutral -> Neutral
2025-10-31 TD Cowen Maintains Buy -> Buy
2025-10-31 Baird Maintains Outperform -> Outperform
2025-10-31 Citigroup Maintains Buy -> Buy
2025-10-31 HC Wainwright & Co. Maintains Buy -> Buy
2025-10-15 Wells Fargo Upgrade Equal-Weight -> Overweight
2025-09-26 Goldman Sachs Downgrade Neutral -> Sell
2025-08-04 JP Morgan Maintains Overweight -> Overweight
2025-08-01 Cantor Fitzgerald Maintains Overweight -> Overweight
2025-08-01 RBC Capital Maintains Sector Perform -> Sector Perform
2025-08-01 Raymond James Maintains Outperform -> Outperform
2025-08-01 Citigroup Maintains Buy -> Buy
2025-07-29 Citigroup Maintains Buy -> Buy
2025-07-18 Baird Maintains Outperform -> Outperform
2025-07-16 B of A Securities Maintains Neutral -> Neutral
2025-07-02 Morgan Stanley Maintains Equal-Weight -> Equal-Weight
2025-06-02 Wells Fargo Maintains Equal-Weight -> Equal-Weight
2025-05-22 Citigroup Maintains Buy -> Buy
2025-05-14 Mizuho Maintains Neutral -> Neutral
2025-05-09 Raymond James Downgrade Strong Buy -> Outperform
2025-05-09 B of A Securities Downgrade Buy -> Neutral
2025-05-08 ScotiaBank Maintains Sector Perform -> Sector Perform
2025-05-08 RBC Capital Maintains Sector Perform -> Sector Perform
2025-05-08 Wells Fargo Maintains Equal-Weight -> Equal-Weight
2025-05-08 Baird Maintains Outperform -> Outperform
2025-05-07 Needham Maintains Buy -> Buy
2025-04-29 Cantor Fitzgerald Initiate Overweight
2025-04-21 RBC Capital Maintains Sector Perform -> Sector Perform

APELLIS PHARMACEUTICALS INC / APLS FAQ

What do analysts expect the price target to be for APELLIS PHARMACEUTICALS INC (APLS)?

28 analysts have analysed APLS and the average price target is 36.24 USD. This implies a price increase of 52.32% is expected in the next year compared to the current price of 23.79.


Can you provide the consensus rating for APELLIS PHARMACEUTICALS INC stock?

The consensus rating for APELLIS PHARMACEUTICALS INC (APLS) is 77.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts have analysed APELLIS PHARMACEUTICALS INC (APLS)?

The number of analysts covering APELLIS PHARMACEUTICALS INC (APLS) is 28.